Datar Cancer Genetics – a leading global company in molecular oncology, specializing in the development of innovative non-invasive solutions based on liquid biopsy (blood tests) for screening (early detection), diagnosis, management, and monitoring of cancer treatment.
The modern medical laboratories of Datar Cancer Genetics, located in the USA, UK, and India, are accredited/certified to ISO 15189, TUV, UKAS, CAP, and CLIA standards.
Datar Cancer Genetics offers its solutions to leading healthcare systems, national and international cancer research institutes, and service providers in the United States, United Kingdom, European Union, as well as the Gulf countries, and India.
Datar Cancer Genetics' innovative solutions for the early detection of breast, prostate, and brain cancers have received 'Breakthrough Designation' status from the FDA (USA).
Go to the company website